German China India

Switzerland: Biopharmaceutical Industry

Lonza Acquires Hanse Biomed Life Sciences and Invests in Exosomics

| Editor: Alexander Stark

Lonza has acquired Hansa Biomed Life Sciences and has invested into Exosomics Siena to develop next-generation research, therapeutic and diagnostic applications based on exosomes.
Lonza has acquired Hansa Biomed Life Sciences and has invested into Exosomics Siena to develop next-generation research, therapeutic and diagnostic applications based on exosomes. (Source: Lonza)

Lonza announced the acquisition of Hansa Biomed Life Sciences, based in Tallinn, Estonia, and a strategic investment into Exosomics Siena, Italy.

Basel/Switzerland — Exosomes are nano-sized vesicles released by all living cells in a finely regulated manner. They are found in biological fluids and contain genetic material, proteins and other cellular molecules reflecting the characteristic of their cells of origin. Functioning as nano-bullets with multiple surface receptors for crossing biological barriers, tissue targeting and delivery of bioactive molecules, they have the potential of being developed for various applications in life sciences.

Exosomes’ acknowledged role as effectors in tissue regeneration, immune response and inflammation shows their potential as the next generation of vaccine development, drug delivery and off-the-shelf, cell-free regenerative therapies.

“Exosomes represent a dynamically growing segment in life sciences with opportunities in research, diagnostics and therapeutic applications,” said Dr. Uwe Gottschalk, Chief Technology Officer for Lonza Pharma & Biotech. “Exosomes may play an important role in the promising field of liquid biopsies and could become the next generation of cell-free therapies in regenerative medicine," he added.

Dr. Antonio Chiesi, managing director of HBM-LS and Chief Executive Officer of Exosomics, said, “The next step in the evolution of exosome technology into diagnostics and therapeutics is the development of larger-scale procedures for isolation, purification and characterization of specific types of exosomes. Cell-culture capabilities are a critical component of this next step. Lonza’s infrastructure and leadership role in bio-manufacturing, combined with our exosome knowledge, will accelerate the availability of these breakthrough modalities.”

As a new part of Lonza, HBM-LS will continue its product portfolio expansion of research products and support the development of cGMP-compliant exosome manufacturing processes. The investment in Exosomics will help to support the continued research, development and pre-commercialization of non-invasive, exosome-based liquid biopsy cancer-screening tests, the company said.

Behzad Mahdavi, Ph.D., MBA, Vice President of Strategic Innovation & Alliances for Lonza Pharm a& Biotech, will be an active member of the Exosomics Board of Directors and will help the company with its strategic market positioning and growth.

Comments are being loaded ....

Leave a comment
  1. Avatar
    Avatar
    Edited by at
    Edited by at
    1. Avatar
      Avatar
      Edited by at
      Edited by at

Comments are being loaded ....

Report comment

Kommentar Freigeben

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

Freigabe entfernen

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

copyright

This article is protected by copyright. You want to use it for your own purpose? Infos can be found under www.mycontentfactory.de (ID: 44701130 / Pharma & Food)